concerns. (6) Intimate care products (especially douches and powders) have been associated with higher levels of toxic chemicals in the bodies of people who use them. Specifically, phthalate levels in urine were significantly higher in people who douche frequently. Another study found significantly higher levels of 1,4–dichlorobenzene in the blood of people who douche frequently and higher levels of ethylbenzene in the blood of intimate powder users. (7) Research regarding the presence of chemicals in menstrual products and intimate care products plays a role in advancing health equity for populations that have historically experienced health disparities, including Black people. (8) Regulatory oversight of the safety of materials in menstrual and intimate care products is limited. The Food and Drug Administration has historically relied on data provided by manufacturers of menstrual products in determining product safety. Intimate care products generally do not need approval by the Food and Drug Administration before they go on the market, and manufacturers have the responsibility to ensure the safety of their products. 3. Research on dioxins and other potentially harmful components of menstrual products and intimate care products Part F of title IV of the Public Health Service Act ( 42 U.S.C. 287d et seq. ) is amended by adding at the end the following new section: 486C. Research on dioxins and other potentially harmful components of menstrual products and intimate care products (a) Research (1) In general The Director of NIH shall provide for the conduct or support of research to determine the extent to which the presence of dioxins, phthalates, titanium dioxide, and other components (including contaminants and substances used as fragrances, colorants, dyes, and preservatives) in tampons and other menstrual products and intimate care products— (A) poses any risks to the health of people who use the products, including risks related to gynecologic, breast, and other cancers, endometriosis, infertility and